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Abstract. Respiratory syncytial virus (RSV) infection repre-
sents an excellent paradigm of precision medicine in modern 
paediatrics and several clinical trials are currently performed 
in the prevention and management of RSV infection. A new 
taxonomic terminology for RSV was recently adopted, while 
the diagnostic and omics techniques have revealed new 
modalities in the early identification of RSV infections and for 
better understanding of the disease pathogenesis. coordinated 
clinical and research efforts constitute an important step in 
limiting RSV global predominance, improving epidemiolog-
ical surveillance, and advancing neonatal and paediatric care. 
This review article presents the key messages of the plenary 
lectures, oral presentations and posters of the ‘5th workshop 
on paediatric virology’ (Sparta, Greece, 12th October 2019) 
organized by the Paediatric Virology Study Group, focusing 
on recent advances in the epidemiology, pathogenesis, diag-
nosis, prognosis, clinical management and prevention of RSV 
infection in childhood.
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1. Introduction
Precision medicine has evolved in recent years allowing the 
incorporation of novel taxonomies and stratification of patients, 
and using standardized clinical endpoints, genetic and other 
biomarker information (1). Its role in paediatric healthcare 
involves the selection of targeted diagnostic, therapeutic and 
prevention strategies matched to precise molecular, epidemio-
logical and clinical profile of each patient; the management of 
respiratory syncytial virus (RSV) infection represents a good 
paradigm of precision medicine (2). RSV is a single-stranded 
RNA virus (Figs. 1 and 2), which represents the most frequent 
viral cause of acute lower respiratory tract infection (ALRTI) 
in infants, with a worldwide distribution and seasonal occur-
rence (2‑5). It was first isolated in 1956 from nasal secretions of 
chimpanzees with rhinorrhea and coryza; the novel virus was 
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initially named ‘chimpanzee coryza agent’ (ccA) (6,7). In the 
following year, when ccA was also isolated from children with 
ALRTI, it gained its final name due to the syncytia observed on 
electron microscopy; syncytia are formed by fusion of infected 
host cells with neighboring cells leading to the formation of 
multi-nucleate enlarged cells. Although the formation of 
syncytia is the hallmark of the cytopathic effect of RSV that is 
associated with host cellular membrane merging, syncytia are 
not pathognomonic of RSV (8). Syncytia are also observed in 
cell culture with several other viruses, such as parainfluenza, 
HSV-1, HIV and MeV. Recently, the International committee 
on Taxonomy of Viruses (IcTV), which authorizes and orga-
nizes the classification and naming of viral species, grouped 
RSV under the genus Orthopneumovirus within the family 
Pneumoviridae (9,10).
Bronchiolitis is the most common clinical manifestation of 
RSV infection in infants and although it is usually self-limiting, 
in infancy it accounts for a significant number of hospitaliza-
tions and paediatric intensive care unit (PIcU) admissions (3). 
despite its association with relatively high morbidity and 
mortality in premature neonates and in certain paediatric 
populations with underlying conditions, such as immuno-
deficiency and congenital heart disease, RSV infection may 
also lead to hospitalization of previously healthy, full-term 
infants (11,12). RSV-positive bronchiolitis is characterized 
by airway inflammation and oedema, mucus production and 
debris leading to airway obstruction and turbulent gas flow. 
Even though various therapeutic interventions have been tried, 
such as bronchodilators, hypertonic saline and corticosteroids, 
supportive care remains the mainstay in most settings, with 
gentle suctioning of nasal secretions, prone position, fluid 
replacement and oxygen or respiratory support, as necessary. 
Several clinical trials on the management and prevention of 
RSV-positive bronchiolitis have been recently completed, 
are underway, or in development (3). currently, there is rapid 
expansion of RSV vaccine candidate development and there 
is hope that one will become available in the near future. Of 
course, the safety of vaccines proposed for primary immuni-
zation in an antigen naïve child remains the top priority.
This review article summarizes the key messages of 
the plenary lectures, oral presentations and posters of the 
‘5th Workshop on Paediatric Virology’ held in Sparta 
(Greece) on October 12th, 2019, which was focused on RSV 
(Table I). This workshop was organized by the Paediatric 
Virology Study Group (PVSG) and was co-chaired by 
dr Simon B. drysdale, consultant and Honorary Senior 
Lecturer in Paediatric Infectious diseases at St. George's 
University Hospital NHS Foundation Trust and St. George's, 
University of London (London, UK), Professor Barbara Rath, 
co-founder and chair of the Vienna Vaccine Safety Initiative 
(Berlin, Germany), Honorary Professor of Nottingham School 
of Medicine (Nottingham, UK) and Research director at the 
University of Bourgogne-Franche-comté (Besançon, France), 
Professor Maria Theodoridou, Professor Emerita of Paediatrics 
at the University of Athens School of Medicine (Athens, 
Greece), President of the National Immunisation committee 
and f. President of the Hellenic Paediatric Infectious diseases 
Society, dr Georgia Papaioannou, Head of the Paediatric 
Radiology department at ‘Mitera’ children's Hospital in Athens 
(Greece), dr Ioannis N. Mammas, consultant Paediatrician on 
the island of Euboea (Greece) and coordinator of the PVSG 
and Professor George P. chrousos, Professor Emeritus of 
Paediatrics and Endocrinology at the University of Athens 
School of Medicine (Athens, Greece). The workshop was held 
under the auspices of the World Academy of Sciences (WAS) 
and was supported by the Laboratory of clinical Virology 
of the University of crete School of Medicine and the First 
department of Paediatrics of the University of Athens School 
of Medicine.
2. Epidemiology of RSV infection
Understanding the burden of RSV infections in real‑time. 
RSV poses significant disease burden in infants and children 
worldwide (13), and the international paediatric community 
is only beginning to appreciate its global impact in both high 
and low resource settings (4,14,15). The clinical presenta-
tion of an RSV infection depends on the patient's age and 
individual risk factors (16,17). The concept of measuring 
individual-level differences in disease severity has drawn the 
attention of both public health stakeholders and regulatory 
agencies in recent years (18-20). The impact of RSV infections 
of course should be differentiated from the disease caused 
by influenza and other viral respiratory infections (21,22). 
However, a recent extensive literature review and prospective 
cohort have shown that in infants and children this cannot be 
done based on clinical symptoms alone; distinguishing RSV 
from other viral respiratory infections requires laboratory 
confirmation (23,24). With RSV vaccines and antiviral agents 
in development, it will be important to: a) diagnose RSV 
infections in a timely manner; b) differentiate RSV from other 
forms of acute respiratory infections; and c) communicate the 
test results back to patients and parents/caregivers along with 
information on the individual disease risk and severity.
The PEDSIDEA programme. The Vienna Vaccine Safety 
Initiative (ViVI, https://www.vi-vi.org) is an international 
non‑profit research organization which, in collaboration with 
academic institutions and public health agencies in Europe and 
the United States, has developed digital tools and programs 
to improve the quality of care for children and adults with 
ALRTI or influenza‑like illnesses (ILI) (13,25,26). Taking a 
person-centered approach, the ViVI disease Severity Score 
(‘ViVI Score’) is a mobile application enabling healthcare 
professionals to measure disease severity at the point of 
care within minutes. It was designed to provide a uniform 
approach to define ad hoc severity at any given time point, 
based on extensive literature review as well as WHO criteria 
for uncomplicated and complicated ILI (27). In collaboration 
with the Robert Koch Institute, the ViVI Score was validated 
in a cohort of 6,000 children (age 0-18) in Berlin, Germany 
and subsequently used in a European pilot project entititled 
‘Partnering for Enhanced Digital Surveillance of Influenza‑like 
disease and the Effectiveness of Antivirals and Vaccines’ 
(PEdSIdEA) (27,28). Since then, the PEdSIdEA programme 
has been implemented in community clinic networks and adult 
intensive care units in the Unites States for the real-time digital 
surveillance of influenza and RSV disease incidence and 
severity at the point of care (29). The programme is expected 
to continue monitoring, in great detail, the clinical outcomes 
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of ‘natural’ RSV and other viral respiratory infections in 
children and adults, including patients at the extremes of age. 
Understanding the real-world disease burden may help facili-
tate the study of the effectiveness of novel influenza and RSV 
antiviral agents and vaccines, once they become available (30).
RSV infection: not for children only. RSV was not recognized 
as a potentially serious problem in older adults until the 
1970s, when outbreaks of the virus occurred in long-term care 
facilities for the elderly (31-33). Since then, additional studies 
in hospitalized adults have suggested that RSV may be an 
important cause of illness in adults. Molecular diagnostics 
suggest that RSV positive specimens are commonly identified 
in elderly and high-risk adults, in a frequency similar to that 
of seasonal influenza (31,34). Even though a positive RSV 
respiratory panel does not equate pathogenesis, it has been 
suggested that RSV may account for as much as 10,000 deaths 
annually in the United States among individuals above the age 
of 65 years (31-33,35). This, in addition to the morbidity in 
infants, has stimulated interest in RSV vaccines and antiviral 
agents. Additional natural history studies are needed to better 
understand the actual burden of RSV infection among the 
elderly and high-risk adults.
3. Pathogenesis, diagnosis and prognosis of RSV infection
The immune response to RSV infection. Maternal antibodies 
may be able to mitigate RSV disease severity in young 
infants (17,36-38). It is assumed that the transplacental passage 
of RSV-specific antibodies occurs predominately during 
the third trimester of pregnancy. High titers can potentially 
protect term infants up to four months of age (38). In prema-
ture infants, passive immunity may be ‘compromised’ (39), but 
still has a role to play. The degree to which breast feeding may 
also contribute to passive immunity and to priming of immune 
system is currently under investigation (40). Once infection is 
established, the innate immune system plays a dual role in 
lowering the viral load and in mounting a secondary immune 
response. Prematurity and other conditions that compromise 
the immune response may lead to reduced levels of antiviral 
cytokines, such as the interferons (41). In infants, reduced 
signaling by TLRs and altered antigen-presenting cell func-
tions, including low interleukin (IL)-12 and enhanced IL-6 and 
IL-23 production, coupled with reduced activation of regula-
tory T cells, may result in an adaptive response that is skewed 
toward Th2 and Th17 and away from protective Th1 and cTL 
responses (42). The potential specific role(s) of certain pattern 
recognition receptors in humans has/ve been suggested by the 
fact that certain TLR missense mutations are associated to a 
phenotype with propensity to wheezing (43). Apart from the 
individual genetics (44), the stage of lung maturation among 
term and premature infants also impacts on the Th1 to Th2 
switch. In the case of prematurity, the mucosa prior to alveo-
larization is being deluged with Th2 inflammatory responses, 
even in the earlier stages of bronchopulmonary dysplasia (45). 
Impaired Th1 activation, coupled with little or no B cell 
memory, and inhibition of antibody production by IFNγ, 
produces low‑titer, low‑affinity antibody (46). The result may 
be a poorly protective and dysregulated defense mechanism 
that leads to bronchiolitis in susceptible infants (43). Later, the 
host immune response is permanently oriented to the direction 
of wheezing exacerbations, specifically triggered by RSV (47).
MicroRNAs as potential bio‑markers in RSV infection. 
MicroRNAs (miRNAs) are involved in post-transcriptional 
gene regulation and play significant roles in the maintenance 
of the airway epithelial barrier of the respiratory tract (48-56). 
miRNAs have been implicated in the modulation of antiviral 
defense mounted by host innate and adaptive immunity, 
involving not only immune effector and inflammatory cells, 
but also parenchymal cells (50). Respiratory viruses, including 
RSV, attack, as a primary target, the epithelial cells of the 
respiratory tract causing an altered expression of distinct 
miRNAs in the airway cells. The human innate immune 
response inhibits RSV replication early after inoculation, 
mainly through the action of interferons (53). Multiple miRNAs 
are induced by infection in a cell‑type‑specific fashion (51). 
RSV appears to alter host cell gene expression also through 
regulation of expression of miRNAs related to the interferon 
response (50,53). Abnormal expression of miRNAs has been 
detected in both peripheral blood cells and airway epithelial 
cells in RSV-infected infants (54). Understanding alterations 
in miRNA expression profiles and identifying miRNA target 
genes in relation to the pathogenesis of RSV may help clarify 
the mechanisms of virus-host interactions, and immune 
dysfunction leading to airway hyper-reactivity and chronic 
respiratory diseases, such as asthma (49,50,53,54). There 
are several methods for the purification, quantification and 
Figure 1. Schematic structure of RSV. The virus envelope contains the fusion 
protein (F), the small hydrophobic protein (SH) and the attachment protein 
(G). Underlying the envelope is the matrix protein (M). The nucleocapsid 
consists of single-stranded RNA (ss RNA) encapsulated by the nucleoprotein 
(N). Associated with the nucleocapsid are the RNA polymerase (L) and the 
phosphoprotein (P). RSV, respiratory syncytial virus.
Figure 2. RSV genome organisation. Genes are listed in sense (coding) 
orientation (3'-to-5') in which each box represents a gene encoding a 
separate mRNA for each protein. NS1 and NAS2, nonstructural proteins; N, 
nucleoprotein; P, phosphoprotein; M, matrix protein; SH, small hydrophobic 
protein, G, attachment proteins; F, fusion protein; M2, second matrix protein; 
L, RNA polymerase; RSV, respiratory syncytial virus.
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Table I. The top key messages of the ‘5th workshop on paediatric virology’ on RSV infection in children.
Epidemiology of RSV infection Being able to compare severity over time and/or across cohorts is useful in hospital-based
 QI programmes but also in multi-centre networks, such as PEdSIdEA
 Understanding the real-world disease burden caused by RSV will facilitate the study of
 the effectiveness of antivirals and vaccines, once they become available
 Recent epidemiological data indicate that RSV infection is an important illness in elderly
 and high‑risk adults, with a disease burden similar to that of non‑pandemic influenza
RSV and immune response Maternal RSV‑specific antibodies transmitted transplacentally during the third trimester
 of pregnancy are related to RSV disease severity in young infants
RSV and miRNAs A greater understanding of miRNAs may enable them to be used as biomarkers of severe
 RSV infection and as novel targets for treatment or prophylaxis of RSV infection
RSV and thrombocytosis Thrombocytosis in RSV-positive bronchiolitis does not require routine prophylactic
 anti-platelet treatment or further investigations
RSV and asthma There is compelling evidence that severe respiratory infection induced by RSV is
 associated with subsequent development of asthma later in childhood
 Further understanding of the role of RSV in asthma pathogenesis will enable our
 understanding of the impact of future vaccines against RSV in asthma prevention
RSV as a cause of PIBO There are only few reports in the literature of children with PIBO secondary to RSV as
 a single infection
 Further research is required in order to investigate the potential impact of RSV
 co-infection in the severity and worse outcome in children with PIBO
Imaging of RSV infection Although imaging cannot diagnose RSV infection, it is important to identify the possible
 pattern of viral disease, in order to avoid unnecessary administration of antibiotic therapy
 and predict possible late effects
 Standard radiological techniques, including cT, are unable to distinguish between acute
 bronchiolitis caused by RSV versus that caused by other respiratory viruses
 HRcT of the lungs may be required to assess possible bronchial thickening and
 remodeling, the development of bronchiectasis and air-trapping
Antivirals against RSV Ribavirin is currently the only licensed antiviral medication used to treat RSV infection; 
 it has very limited efficacy and multiple toxicities, which means its use is usually
 reserved for severely immunocompromised children
 due to ethical and technical constraints human challenge models are only undertaken in
 adults, but if a product is shown to be efficacious in this setting it allows a faster move
 to trials in children than traditional trials which often take much longer to do
 A greater understanding of individual data in newly developed pharmaceutical agents
 against RSV will potentially lead to future personalized treatment regimens
RSV and PIcU HFNc might have a role as a rescue therapy for children with RSV-positive bronchiolitis
 admitted to PIcU to reduce their requirement for high-cost intensive care
 Heliox could be useful in addition to standard medical care in the management of
 children with RSV-positive bronchiolitis admitted to PIcU
Prevention of RSV infection To date, there is only one product available for prevention of RSV infection, 
 palivizumab, the mAb that has been shown to reduce hospital admission due to RSV
 infection in some high risk infants by up to 80%
 There are currently 43 RSV vaccines in development; of these, 21 are in clinical trials
 in humans; 14 in Phase 1, five in Phase 2 and two in Phase 3, 12 vaccines are in trials in
 children, 4 in pregnant women and 10 in older adults
 A possible route to licensure is currently being sought with the US FdA and European
 licensing agencies for a maternal RSV vaccine, bringing hope of a vaccine becoming
 available that could save the lives of countless young infants worldwide
RSV, respiratory syncytial virus; mAb, monoclonal antibody; FDA, Food and Drug Administration; QI, quality improvement, PEDSIDEA, 
Partnering for Enhanced Digital Surveillance of Influenza‑like Disease and the Effectiveness of Antivirals and Vaccines; ALRTI, acute lower 
respiratory tract infection; ILI, influenza‑like illness; CT, computed tomography; HRCT, high‑resolution computed tomography; ICTV, 
International Committee on Taxonomy of Viruses; miRNAs, microRNAs; PIBO, post infectious bronchiolitis obliterans; PICU, Paediatric 
Intensive Care Unit; HFNC, high‑flow nasal cannula.
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characterization of miRNA expression profiles in biofluids, 
whole blood samples and tissue samples obtained in in vivo 
studies (55). Further research on miRNAs is expected to 
clarify their value as biomarkers of RSV infections and their 
sequelae (i.e., recurrent wheezing and asthma).
Thrombocytosis and RSV infection. The most frequent causes 
of secondary thrombocytosis in childhood are acute respira-
tory tract infections (57-61). To date, several authors have 
reported significantly higher mean platelet counts in patients 
with RSV than in patients with other acute respiratory tract 
infections (61-64). Thrombocytosis is more likely to occur 
in younger patients, who have clinical manifestations of 
wheezing and dyspnoea (62,64). Moreover, thrombocytosis 
has been suggested as an early marker of RSV infection (62). 
Excessive thrombocytosis has also been detected at an early 
stage in cases of RSV-positive bronchiolitis (65). It has been 
proposed that thrombocytotic patients have a more severe 
clinical course and longer duration of hospitalization and that 
the platelet count may be a useful clinical marker associated 
with ALRTI severity (61,64,66,67). conversely, other authors 
have found that platelet counts do not correlate with disease 
severity and clinical outcome (68,69). Routine prophylactic 
anti-platelet treatment or further investigations are not 
necessary in children with RSV-positive bronchiolitis and 
thrombocytosis (61,68,70).
RSV‑positive bronchiolitis and asthma. There is compelling 
evidence that infants with severe RSV infection in the early 
months of life have a subsequent increased risk of developing 
recurrent wheezing and/or asthma, with a prevalence of up 
to 30% compared with non-RSV groups (71-75). Whether 
this association is causal has been the subject of considerable 
debate on the potential role of RSV infection in the pathogen-
esis of asthma as well as the impact of asthma predisposition 
(genetic, environmental exposure, etc.) on the clinical course 
of RSV infection. A recent large retrospective cohort analysis 
of Australian children born between 2000 and 2010 suggested 
that different subgroups of high risk children, who developed 
RSV disease within the first 2 years of life, continued to be at 
elevated risk of having a first asthma hospitalization beyond 
the age of 7 years (76). On the other hand, large epidemiolog-
ical observational studies demonstrate that the vast majority 
of infants hospitalized for RSV bronchiolitis do not fit into 
an ‘at-risk’ group (atopy, family history, etc.), suggesting that 
viral or host factors not thought of as classical risk factors, 
may play a role in disease severity (74,77). Prospective studies 
with RSV-immunoprophylaxis (e.g., palivizumab) suggest that 
long‑term effects of RSV prophylaxis appear less efficacious 
in infants with a family history of atopy. In addition, palivi-
zumab decreases parent-reported recurrent wheeze, however 
the incidence of physician-diagnosed asthma is similar (78). 
A recent single-blind, randomized, placebo-controlled trial 
showed that RSV prevention in otherwise healthy preterm 
infants, did not have a major effect on asthma or lung function 
at the age of 6 years (79).
Considering the above findings, perhaps a more appropriate 
conclusion would be that RSV infection is important in the 
mechanism of wheezing development, at least in the first few 
years of life (80). RSV possesses the ability to counteract host 
defense systems through complex mechanisms that facilitate 
viral replication. This significant increase in asthma frequency 
seems to be predominantly related to long-term changes in 
neuroimmune control of airway tone rather than to allergic 
sensitization. In contrast to RSV bronchiolitis, atopy has been 
clearly associated with childhood asthma development after 
RSV-induced early wheezing (81,82). High-risk (parental atopy 
or asthma) birth cohort studies from Wisconsin, United States, 
and Australia have shown that young children suffering from 
RSV-induced wheezing episodes are at high risk of developing 
school-age asthma (81,82). Further prospective, follow-up 
studies are needed to clarify individual and environmental 
factors that promote more severe viral illnesses and long-term 
adverse respiratory outcome of children hospitalized for severe 
RSV infection. developing a greater understanding of the 
pathophysiological mechanisms through which RSV causes 
recurrent wheezing/asthma, will lead to an evidence-based 
prevention strategy and perhaps reduce the subsequent risk for 
asthma (71).
Predicting asthma following RSV‑positive bronchiolitis. 
The biomarker ccL5 (previously known as RANTES, 
a β-chemoattractant for inf lammatory cells including 
T-lymphocyte subsets), in the nasal epithelium during RSV 
bronchiolitis, is strongly predictive of physician-diagnosed 
asthma (83,87). Furthermore, it has been suggested that 
prematurely born infants have a predisposition to RSV 
infection-related respiratory morbidity, including subsequent 
respiratory dysfunction (44,85). Single-nucleotide poly-
morphisms in genes coding for IL-8, IL-19, IL-20, IL-13, 
mannose-binding lectin, IFNG and RANTES, have been 
associated with wheezing following RSV LRTI in term-born 
infants (85). The site of infection might be another important 
factor related to asthma risk, thus viral ALRTI in infancy 
indicates an increased risk of subsequent asthma, while 
gastrointestinal infections might be protective (86). Asthma 
after severe RSV bronchiolitis is positively correlated with 
maternal asthma, exposure to high levels of dog allergen, 
aeroallergen sensitization and recurrent wheezing; day care 
attendance and white race have been associated with decreased 
asthma risk (87). Several host factors, including respiratory 
allergy and virus-induced interferon responses, viral virulence 
factors, individual risk factors (e.g., young age, especially the 
first 6 months of life, small lung size and genetics), and envi-
ronmental exposures (e.g., exposure to tobacco smoke, airway 
microbiome) modify the risk of virus-induced wheezing and 
promote more severe wheezing illnesses and the risk for 
progression to asthma (86,88). The anti-RSV mAb palivi-
zumab decreases the risk of severe RSV-induced illness and 
subsequent recurrent wheeze in prematurely born infants (89). 
Further understanding of the role of RSV in asthma patho-
genesis may help develop vaccines against RSV as a way of 
asthma prevention.
Post infectious bronchiolitis obliterans caused by RSV. 
Bronchiolitis obliterans (BO) is a chronic and irreversible 
lung disease leading to the obstruction and/or obliteration 
of the small airways (90). Most cases of BO in children 
are post infectious (PIBO) and are mainly associated with 
adenovirus infections, although other viruses may also be 
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implicated, including measles, influenza, parainfluenza and 
RSV (91-93). An extensive search of the current literature in 
the context of the workshop demonstrated that RSV is detected 
in children with PIBO with an incidence ranging from 4.3 to 
30% (94‑103); however, there are only a few reports of chil-
dren with PIBO secondary to RSV as a single infection. This 
creates skepticism about the aetiological role of RSV in PIBO. 
Further research is required to investigate the potential impact 
of RSV co-infection in the severity and outcome of children 
with PIBO.
4. Imaging in children with RSV infection
Chest radiography and RSV‑positive bronchiolitis. Although 
imaging cannot confirm the diagnosis of RSV infection, it 
is important to identify the possible pattern of viral disease, 
in order to avoid unnecessary administration of antibiotic 
therapy and to predict possible late effects (Figs. 3-5) (104). 
The clinical syndrome of bronchiolitis is commonly diagnosed 
based on the patient's history and physical examination; chest 
radiography is not routinely recommended to reach the diag-
nosis due to recommended restriction of radiation exposure in 
the paediatric age group (104-106). chest imaging, however, 
may be considered when a child with RSV infection and 
severe ALRTI is admitted to intensive care to better under-
stand the extent of lung involvement and atelectasis, which is 
common in acute RSV infection (106). It is important to note 
that chest radiographs in children with RSV infection may 
be entirely normal or reveal non‑specific findings, which are 
also encountered in other viral infections: most commonly, 
perihilar opacities and hyperinflation, atelectasis and 
rarely consolidation and bronchial cuffing or air‑leak (107). 
Radiography is commonly obtained to rule out atelectasis and 
foreign body aspiration. Guidelines suggest performing a chest 
radiograph in the presence of significant respiratory distress 
or hospitalization (108). In newborns with RSV infection, the 
radiological pattern on chest radiography may be a predictor 
of clinical outcome (109). However, it is highlighted that chest 
radiographs should not be routinely performed in children 
with bronchiolitis to avoid radiation exposure (106). It is also 
important to emphasize that chest radiograph is not the right 
way to rule out bacterial infection (106); the correct diagnostic 
approach for bacterial or ventilator-associated pneumonia 
in children in the PIcU is to perform respiratory culture or 
Matrix-assisted laser desorption ionization time-of-flight 
(MALdI-TOF) mass spectrometry from sputum/aspirate or 
bronchoalveolar lavage (BAL) specimens.
Chest CT and RSV‑positive bronchiolitis. Several studies 
have revealed that standard radiological techniques, including 
computed tomography (cT), are frequently unable to distin-
guish between acute bronchiolitis changes caused by RSV 
vs. those caused by other respiratory viruses (104,108). It 
is interesting that the radiographic findings, especially in 
Figure 3. chest radiograph of a 14-month-old girl admitted to hospital with 
RSV‑positive ALRTI. There is hyperinflation of the lungs and presence of 
bronchial wall cuffing (arrows), without evidence of consolidation or effu-
sion. RSV, respiratory syncytial virus; ALRTI, acute lower respiratory tract 
infection.
Figure 4. HRcT of the lungs of the same child as Fig. 3 using controlled 
ventilation technique, performed 4 months later due to recurrent bronchiolitis. 
Transverse thin-section cT scan through the upper lobes shows bilateral 
bronchial wall thickening (arrows) without evidence of bronchiectasis. 
HRCT, high‑resolution computed tomography; CT, computed tomography.
Figure 5. Same child; expiratory transverse thin‑section CT scan through 
the same level as Fig. 4 reveals hyperlucent areas of air-trapping bilaterally 
(arrows). cT, computed tomography.
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high‑resolution computed tomography (HRCT), reflect the 
histopathologic changes that RSV infection provokes: plugging 
or occlusion of the bronchiolar airway lumens by sloughed 
necrotic and irregular epithelium and exudate, combined with 
peri‑bronchiolar infiltration and reaction with inflammatory 
cells and submucosal oedema. The infiltration is a combination 
of neutrophils entering the airway submucosa and epithelial 
cell debris in the airway lumens. These cellular accumulations 
are likely to result in acute obstruction of the distal airways, 
an outcome much more likely to occur in the extremely narrow 
bronchioles of infants. Because this is combined with the 
inherent loss of mechanical clearance of these small airways, 
it likely leads to increased spread of infection, augmented 
inflammation and clinical signs of wheezing/obstruction (110). 
Consistent with obstruction, the most common CT findings in 
RSV pneumonia include centrilobular nodules, ground-glass 
opacities, air-space consolidation, and peribronchial thick-
ening (111). These findings have a bilateral, usually asymmetric, 
central and peripheral distribution. Up to 40% of children with 
bronchiolitis will develop further wheezing episodes in the 
first five years of life. In very severe or atypical cases, HRCT 
of the lungs may be required to assess the extent of bronchial 
thickening and remodeling, the development of brochiectases 
and air-trapping (105).
CNS imaging and RSV infection. RSV infection is not always 
restricted to the airways. case reports have also described 
clinical pictures resembling viral encephalitis and/or 
encephalopathic syndromes with severe sequelae in isolated 
cases (112). The mechanism of the spread of the RSV infec-
tion to the cNS compartment remains unclear (112). Brain 
magnetic resonance imaging (MRI) in infants with cNS 
involvement has shown predominantly non-specific find-
ings similar to those also encountered in other viral and/or 
limbic system encephalitides (113). In very rare instances, 
extra‑pulmonary findings in RSV infection have also included 
acute necrotizing encephalopathy (ANE) and acute hepatic 
failure with encephalopathy (114). clinicians should have a 
high suspicion of ANE in cases of children with a respiratory 
infection and acute neurological manifestations.
5. Therapeutics of RSV infection
Antivirals against RSV. Thus far, ribavirin is the only antiviral 
agent that has ever been licensed for the treatment of RSV 
infection (115). However, its efficacy is not proven and due 
to significant toxicity its use has been primarily restricted 
to severe cases in immunocompromised patients with severe 
RSV-positive ALRTI (116). Several other antiviral candidates 
have been developed since, but none have been licensed 
as yet. Types of molecules being tested include influenza 
antivirals, such as baloxavir, cc-42344, VIS410, immuno-
globulin, hyperimmune plasma, MHAA4549A, pimodivir 
(JNJ-63623872), umifenovir, and HA minibinders, RSV 
antivirals including presatovir (GS-5806), ziresovir (AK0529), 
lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, 
and EdP-938, broad spectrum antivirals such as favipiravir, 
VH244, remdesivir, and EIdd-1931/EIdd-2801, as well as 
host directed strategies including nitazoxanide, eritoran, and 
diltiazem (117-119). Novel molecules disrupt various stages 
of the virus life cycle, including cell entry, viral replication, 
and polymerization as well as after virus release through RSV 
neutralizing anti- or nanobodies (120).
The human challenge models. One method used occasionally 
in phase 2 clinical testing is human challenge models (115). 
This method was used in Phase 2a clinical testing of the 
non‑fusion inhibitor EDP‑938 (ClinicalTrials.gov Identifier: 
NcT03691623). All participants were inoculated with a 
known strain of RSV and were then randomized to receive the 
medication or placebo. The advantage of this methodology is 
the removal of the variability in exposure with natural infec-
tion and the collection of samples at precise, known times 
after infection, which can aid with the understanding of the 
biological mechanisms of the infection and development of 
antiviral agents or vaccines (121,122). due to ethical and tech-
nical constraints, experimental studies are only undertaken 
in adults, but if a product is shown to be efficacious at this 
setting, a faster move to trials in paediatrics takes place than in 
traditional childhood trials.
RSV therapeutics and personalized medicine. The current 
clinical data indicate that RSV disease dynamics may not 
be identical in all patients (2,3,115,119). More research is 
needed to identify uniform clinical endpoints reflecting how 
patients function, thrive, and survive (US Food and drug 
Administration) and to understand inter-individual differences 
in disease presentation, with the goal of ultimately selecting the 
right treatment for the right patient. A greater understanding 
of individual differences may ultimately lead to future person-
alized treatment strategies. Individualized approaches and a 
well-standardized methodology to assess disease severity 
at the time of enrolment, as well as during follow-up visits, 
will require integration of diagnostic, clinical and laboratory 
markers at the point of care (115). Individualized targeted 
treatment will constitute an important step in improving 
outcomes in patients with RSV infection while minimizing 
toxicity. A greater understanding of individual data in newly 
developed pharmaceutical agents against RSV will potentially 
lead to future personalized treatment regimens. Applying 
such co-ordinated diagnostic, clinical and research efforts 
constitutes an important step in advancing paediatric care, 
improving outcomes and limiting global RSV morbidity and 
mortality.
High‑flow nasal cannula and RSV‑positive bronchiolitis. 
Over the last decade, high‑flow nasal cannula (HFNC) therapy 
has emerged as a new method to provide respiratory support in 
children with RSV-positive bronchiolitis (12,123-126). Its main 
advantages include its ease to set up and the fact that it is well 
tolerated, leading to better compliance, especially in compar-
ison to other devices of non-invasive ventilation (125,127). 
Initially, HFNc was trialed in infants with moderate to severe 
bronchiolitis admitted to PIcUs, but nowadays its application 
has expanded to paediatric wards, even to emergency depart-
ments, in order to avoid a PIcU admission (127,128). Recent 
data have shown that it does not significantly reduce time 
on oxygen compared with standard therapy, suggesting that 
early use of HFNc does not modify the underlying disease 
process (129). However, the proportion of children who experi-
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ence treatment failure is lower in HFNc and many of those 
who experience treatment failure on standard therapy can 
be rescued by HFNc. Additional studies comparing HFNc 
with continuous positive airway pressure (cPAP) in the PIcU 
setting led to the same conclusion (130,131). consequently, 
HFNc may reduce the need for intubation and invasive respi-
ratory support, thus potentially lowering costs and adverse 
effects of mechanical ventilation, such as ventilator-induced 
lung injury, infections and exposure to sedatives. In addition 
to effectiveness, most studies have shown no adverse events 
with HFNc and have concluded that it is a relative safe method 
for use even in general wards or emergency departments (123). 
Few cases of pneumothorax have been reported, abdominal 
distension has been less significant compared with CPAP, and 
the majority of infants have been able to be fed orally or by 
nasogastric tube (123,127).
Heliox and RSV‑positive bronchiolitis. Since RSV-positive 
bronchiolitis is associated with airway obstruction and 
turbulent gas flow, its clinical course can be improved by 
Heliox, which facilitates gas flow through high‑resistance 
airways (132-138). Heliox is a mixture of helium-oxygen, 
which can be administered by all modes of ventilation in 
spontaneously breathing patients by face mask, HFNc or 
CPAP, and can be adjusted to specific ventilators in intubated 
children. current evidence suggests that the addition of 
Heliox may significantly reduce clinical scores evaluating 
respiratory distress and the respiratory rate, and may enhance 
cO2 elimination in the first hour after starting treatment in 
infants with acute refractory RSV bronchiolitis (134,139). 
Recently, Seliem and Sultan (140) reported that Heliox 
results in improvement of oxygenation when used with high 
flow nasal cannula in infants with acute RSV bronchiolitis, 
during the initial phase of therapy. The combination of Heliox 
with CPAP also seems to be beneficial, as the application of 
CPAP may reduce the fiO2 needed in these infants. However, 
no benefit has been observed in terms of need for intuba-
tion and mechanical ventilation, length of treatment or PIcU 
stay. In addition, its application in the emergency department 
does not change the discharge rate (138,139). More clinical 
trials are needed to define the population that may respond 
to Heliox and its place in the therapeutic regimens of RSV 
bronchiolitis.
6. Prevention of RSV infection
Passive immunization and Palivizumab. The prevention of 
RSV morbidity and mortality remains a global healthcare 
priority (115,141). According to the World Health Organization 
(WHO), the strategic focus for the prevention of RSV infection 
in children and adults includes the passive administration of 
immunoglobulins, as well as active immunization. Passive 
immunization is currently the only option available to infants 
less than 6 months of age, which can be achieved through 
administration of antibodies to the infant or through active 
immunization of the mother during pregnancy. Passive 
immunity wanes fast over time, thus, active immunization is 
the preferred approach for infants above six months of age, 
as well as older children and adults, including the elderly (141). 
To date, there is only one product available for prevention of 
RSV infection, palivizumab, the monoclonal antibody (mAb) 
that has been shown to reduce hospital admission due to RSV 
infection in some high-risk infants by up to 80% (142). It is 
expensive and, thus, reserved for high risk infants, mainly in 
high income countries.
Active immunization against RSV: looking back to the past. 
While antibodies are costly and transitory in their effect, 
active vaccination would represent the most cost-effective 
approach for the prevention of RSV infections and their 
transmission to high-risk individuals (115,141). Up to date, 
several vaccine candidates are in development, but none have 
reached licensure yet (143,144). One of the main barriers for 
the development of RSV vaccines has been the fact that the 
majority of severe cases in infants occur within the first three 
months of life, i.e. at a time when active immunization is not 
really possible (145). Additional caution has been employed 
during vaccine design because of the failure of a historical 
vaccine [formalin inactivated RSV (FI-RSV)], which trig-
gered a severe adverse effect, enhanced respiratory disease 
(ERd) (146). For more than 50 years live-attenuated vaccine 
approaches have been unsuccessful because of the difficulty 
in balancing immunogenicity and vaccine safety. It is worth 
noting that only live-attenuated vaccines have been tested for 
active infant immunization.
Active immunization against RSV: perspectives. Recent 
breakthroughs in determining the structure and antigenic 
content of the RSV fusion (F) glycoprotein has enhanced 
interest in vaccine development research (115,141,147,148). 
The general approaches to vaccine development include 
engineered viruses that use knowledge of RSV gene function, 
naturally attenuated chimeric virus combining genes from 
RSV-related viruses, viral vectors encoding RSV surface 
antigens, and nucleic acid vaccines using plasmid dNA or 
messenger RNA encoding RSV antigens (149,150). As of 
August 2019, 43 RSV vaccines were in development (151). Of 
these, 21 are in clinical trials in humans; 14 in Phase 1, five 
in Phase 2 and two (one just completed) in Phase 3. Twelve 
vaccines are in trials in children, four in pregnant women and 
10 in older adults (some products are undergoing trials in more 
than one target population). Vaccine types under investigation 
include live-attenuated/chimeric, particle-based, subunit and 
recombinant vector vaccines. This highlights the variety and 
breadth of immunization types and different populations that 
are being investigated to find an answer to the 60‑year‑old 
problem of producing a safe and effective RSV prophylactic 
agent.
The ResVax. The most advanced candidate vaccine, ResVax, 
is an RSV fusion protein recombinant nanoparticle with 
aluminum phosphate as an adjuvant (115,152,153). The new 
approach to develop this vaccine is based on engineering 
small particles that carry altered RSV proteins. The nanopar-
ticles sensitize the immune system to the virus so that when a 
person comes in contact with it the immune system delivers a 
robust response. The Phase 3 clinical trial included more than 
4,600 pregnant women examining the efficacy of prevention 
of RSV disease in infants through maternal immunization. 
Although the trial narrowly missed its primary end point 
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of a reduction in medically attended RSV-positive ALRTI, 
it showed a 44% vaccine efficacy against RSV hospitaliza-
tion, 25% efficacy against all respiratory hospitalizations 
and 39% efficacy against all‑cause severe hypoxaemia (152). 
A possible route to licensure is currently being sought with 
the US Food and drug Administration (FdA) and European 
licensing agencies, bringing hope of a vaccine that could save 
the lives of countless young infants worldwide.
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